Browsing ICR Divisions by author "Isacke, Clare"
Now showing items 21-29 of 29
-
Mouse mammary stem cells express prognostic markers for triple-negative breast cancer.
Soady, KJ; Kendrick, H; Gao, Q; Tutt, A; Zvelebil, M; et al. (BMC, 2015-03-04)INTRODUCTION: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours in which chemotherapy, the current mainstay of systemic treatment, is often initially beneficial but with a high risk of relapse and ... -
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Becherini, C; Visani, L; Caini, S; Bhattacharya, IS; Kirby, AM; et al. (ELSEVIER SCI LTD, 2023-09-01)The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become the standard of care for hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, improving ... -
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.
Wagner, S; Vlachogiannis, G; De Haven Brandon, A; Valenti, M; Box, G; et al. (NATURE PUBLISHING GROUP, 2019-03-07)Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed ... -
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Andreucci, E; Francica, P; Fearns, A; Martin, L-A; Chiarugi, P; et al. (IMPACT JOURNALS LLC, 2016-12-06)The majority of breast cancers are estrogen receptor positive (ER+). Blockade of estrogen biosynthesis by aromatase inhibitors (AIs) is the first-line endocrine therapy for post-menopausal women with ER+ breast cancers. ... -
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Soosainathan, A; Iravani, M; El-Botty, R; Alexander, J; Sourd, L; et al. (AMER ASSOC CANCER RESEARCH, 2024-01-02)UNLABELLED: The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor-positive (ER+) breast cancer, yet many patients relapse with ... -
The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesis.
Soady, KJ; Tornillo, G; Kendrick, H; Meniel, V; Olijnyk-Dallis, D; et al. (COMPANY OF BIOLOGISTS LTD, 2017-10-15)PTPRB is a transmembrane protein tyrosine phosphatase known to regulate blood vessel remodelling and angiogenesis. Here, we demonstrate that PTPRB negatively regulates branching morphogenesis in the mouse mammary epithelium. ... -
Therapy-induced normal tissue damage promotes breast cancer metastasis.
Perkins, DW; Steiner, I; Haider, S; Robertson, D; Buus, R; et al. (CELL PRESS, 2024-01-19)Disseminated tumor cells frequently exhibit a period of dormancy, rendering them chemotherapy insensitive; conversely, the systemic delivery of chemotherapies can result in normal tissue damage. Using multiple mouse and ... -
Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness.
Avgustinova, A; Iravani, M; Robertson, D; Fearns, A; Gao, Q; et al. (NATURE PUBLISHING GROUP, 2016-01-18)Stromal fibroblast recruitment to tumours and activation to a cancer-associated fibroblast (CAF) phenotype has been implicated in promoting primary tumour growth and progression to metastatic disease. However, the mechanisms ... -
Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain.
Kijewska, M; Viski, C; Turrell, F; Fitzpatrick, A; van Weverwijk, A; et al. (BMC, 2019-01-14)BACKGROUND: Dissemination of breast cancers to the brain is associated with poor patient outcome and limited therapeutic options. In this study we sought to identify novel regulators of brain metastasis by profiling mouse ...